Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis

Completed · Phase 4

Conditions studied: Cystic Fibrosis

In brief

The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis.

Key facts

Study ID

NCT02444234

Run by

University of Southern California

People needed

11

Starts

2015-07-01

Expected to finish

2017-12-31

Last updated by the study team

2020-06-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of CF based on positive sweat chloride or known CF mutation
• Age > 17 years
• Able to spontaneously expectorate sputum

You may not qualify if…

• Any clinically significant laboratory abnormalities
• Presence of an ongoing acute pulmonary exacerbation
• Pregnancy
• Serious past allergy to linezolid or tedizolid
• No alcohol, nicotine, or caffeine-containing products during the study period

Where it is running

• University of Southern California — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.